Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production.
The current process of influenza vaccine production can take 6-9 months and is dependent on the availability of embryonated eggs. Additionally, this process selects for receptor-binding variants with reduced antigenicity and requires significant downstream production for purification. We have established an immortalized chick embryo cell line, termed PBS-12SF, which is adapted to growth in serum free conditions, and is capable of replicating human and reassortant H5N1 influenza strains to high titers. In many cases, PBS-12SF cells produced higher growth titers of influenza virus than those of primary chick embryo kidney (CEK) cells, Madin-Darby Canine Kidney (MDCK) cells and African green monkey kidney cells (Vero). Additionally, in PBS-12SF cell cultures, influenza virus is released into the culture fluid without need for exogenous proteases, which can simplify downstream processing for vaccine production.